PD-(L)1xVEGF Bispecifics: The New Frontier in Cancer Immunotherapy
In a rapidly evolving landscape of cancer immunotherapy, pharmaceutical giants are racing to secure their positions in the promising field of PD-(L)1xVEGF bispecific antibodies. Recent developments have seen major players like Bristol Myers Squibb (BMS), Pfizer, and Merck & Co. making significant moves, while others such as Eli Lilly and Novartis are closely watching the space.